Bruker Corporation (NASDAQ:BRKR) Receives $53.71 Consensus PT from Analysts

Shares of Bruker Corporation (NASDAQ:BRKR) have been assigned a consensus rating of “Moderate Buy” from the sixteen brokerages that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $53.7143.

A number of brokerages have recently weighed in on BRKR. Bank of America boosted their target price on Bruker from $43.00 to $60.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. Zacks Research upgraded Bruker from a “strong sell” rating to a “hold” rating in a report on Monday, December 8th. Rothschild Redb upgraded Bruker to a “strong-buy” rating in a research note on Thursday, November 20th. Guggenheim raised their target price on Bruker from $53.00 to $58.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Bruker in a research note on Monday, December 29th.

Bruker Trading Down 2.5%

Shares of Bruker stock opened at $42.66 on Friday. The company has a market capitalization of $6.48 billion, a P/E ratio of -266.63, a price-to-earnings-growth ratio of 5.75 and a beta of 1.19. The stock has a fifty day simple moving average of $48.11 and a 200 day simple moving average of $40.47. Bruker has a 12-month low of $28.53 and a 12-month high of $57.92. The company has a current ratio of 1.85, a quick ratio of 0.91 and a debt-to-equity ratio of 0.81.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Monday, November 3rd. The medical research company reported $0.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.33 by $0.12. The firm had revenue of $860.50 million for the quarter, compared to the consensus estimate of $847.40 million. Bruker had a negative net margin of 0.61% and a positive return on equity of 15.45%. The business’s revenue for the quarter was down .5% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.60 EPS. On average, sell-side analysts anticipate that Bruker will post 2.69 earnings per share for the current fiscal year.

Insider Activity

In related news, VP Mark Munch sold 2,000 shares of Bruker stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $49.20, for a total value of $98,400.00. Following the sale, the vice president owned 128,443 shares of the company’s stock, valued at approximately $6,319,395.60. The trade was a 1.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director John A. Ornell sold 6,233 shares of the stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $39.00, for a total value of $243,087.00. Following the transaction, the director directly owned 35,212 shares of the company’s stock, valued at approximately $1,373,268. This trade represents a 15.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 15,233 shares of company stock worth $726,487. Insiders own 27.30% of the company’s stock.

Institutional Trading of Bruker

Hedge funds have recently made changes to their positions in the company. Nisa Investment Advisors LLC grew its stake in shares of Bruker by 377.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company’s stock worth $25,000 after acquiring an additional 487 shares during the period. Huntington National Bank lifted its holdings in Bruker by 750.0% during the second quarter. Huntington National Bank now owns 731 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 645 shares during the last quarter. Spire Wealth Management bought a new position in Bruker during the second quarter worth about $32,000. Allworth Financial LP increased its stake in shares of Bruker by 40.6% in the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after purchasing an additional 257 shares in the last quarter. Finally, True Wealth Design LLC raised its position in shares of Bruker by 16,716.7% in the second quarter. True Wealth Design LLC now owns 1,009 shares of the medical research company’s stock valued at $42,000 after purchasing an additional 1,003 shares during the period. 79.52% of the stock is currently owned by institutional investors.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.